FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2914656225> ?p ?o ?g. }

• W2914656225 endingPage "1705" @default.
• W2914656225 startingPage "1705" @default.
• W2914656225 abstract "Abstract Background Primary central nervous system lymphoma (PCNSL) is rare and aggressive Non-Hodgkin lymphoma of the central nervous system (CNS).High-dose methotrexate (HD-MTX) based chemotherapy is standard first-line treatment in newly diagnosed disease. Although remissions can be achieved in most patients, at least a third relapses and therapeutic options in relapsed/refractory PCNSL (r/r PCNSL) are still limited. Aim of this study was to investigate efficacy and safety in of the R-DeVIC protocol consisting of: rituximab, ifosfamide, dexamethason, carboplatin and etoposide. Methods This was a retrospective study based on routinely collected health data from two sites in Germany (Stuttgart and Freiburg). Patient eligibility criteria were: r/r PCNSL confirmed by local pathology treated with at least one prior therapy. The R-DeVIC protocol was applied according to the following schedule: Rituximab 375 mg/m2/d (d0), dexamethasone 40 mg/d (d1-3), etoposide 100 mg/m2/d (d1-3), ifosfamide 1500 mg/m2/d (d1-3), carboplatin 300 mg/m2/ (d1) and repeated after 21 days. Feasibility endpoints included: toxicity, dose density, and treatment related death. Efficacy endpoints included: response as evaluated on brain MRI, progression free survival (PFS) and overall survival (OS). We used descriptive statistics for summarizing patient characteristics and outcomes; including the Kaplan-Meier estimator to plot time-to-event endpoints. Results We identified 19 eligible patients with r/r PCNSL being treated with R-DeVIC between 2010 and 2018. All patients received prior HD-MTX based chemotherapy (58% (11/19) treated with R-MTX/AraC/Thiotepa, 11% (2/19) treated with R-MTX/AraC and 26% (5/19) treated with R-MTX). All, but 2 patients received R-DeVIC at first progression after 1stline treatment. In 52% (10/19), treatment was discontinued after the first cycle. In 3 patients R-DeVIC was discontinued due to severe infections or renal injury and in 2 patients due to ifosfamide induced neuro-toxicity, as well as progressive disease in 2 patients. 2 patients already achieved complete remission and in one case reasons for discontinuance were not recorded. A 2ndcycle was administered in 47% (9/19) and 3 patients received a 3rdcycles of R-DeVIC. Observed overall response rate after R-DeVIC was 79% (15/19): Five patients with complete and 10 with partial remission, respectively. Three (26%) patients had progressive disease and one patient achieved disease stabilization. Neutropenic fever requiring intravenous antibiotic treatment was the most common adverse event (21% of administered cycles), followed by neurological disturbances, mainly associated with ifosfamide. After a median follow-up of 5 months, 6- month and 12 -month PFS were both 47% (95% CI 24-67); 6 month and 12-month was OS 59% (95% CI 32-78). Conclusions R-DeVIC is a feasible therapeutic salvage option in r/r PCNSL associated with a response rate of 79%. However, substantial toxicity was also observed leading to discontinuation of treatment in about a quarter of patients. Further data will be presented at the meeting. Disclosures Finke: Novartis: Consultancy, Honoraria, Other: travel grants, Research Funding; Medac: Consultancy, Honoraria, Other: travel grants, Research Funding; Neovii: Consultancy, Honoraria, Other: travel grants, Research Funding; Riemser: Consultancy, Honoraria, Research Funding. Illerhaus:Riemser: Consultancy, Honoraria." @default.
• W2914656225 created "2019-02-21" @default.
• W2914656225 creator A5010948621 @default.
• W2914656225 creator A5014728553 @default.
• W2914656225 creator A5017224763 @default.
• W2914656225 creator A5035666187 @default.
• W2914656225 creator A5049307026 @default.
• W2914656225 creator A5061658744 @default.
• W2914656225 date "2018-11-29" @default.
• W2914656225 modified "2023-09-26" @default.
• W2914656225 title "Ifosphamide and Carboplatin Based (R-DeVIC) Salvage Therapy in Patients with Relapsed/Refractory PCNSL - a Multicentre Retrospective Analysis" @default.
• W2914656225 doi "https://doi.org/10.1182/blood-2018-99-117329" @default.
• W2914656225 hasPublicationYear "2018" @default.
• W2914656225 type Work @default.
• W2914656225 sameAs 2914656225 @default.
• W2914656225 citedByCount "0" @default.
• W2914656225 crossrefType "journal-article" @default.
• W2914656225 hasAuthorship W2914656225A5010948621 @default.
• W2914656225 hasAuthorship W2914656225A5014728553 @default.
• W2914656225 hasAuthorship W2914656225A5017224763 @default.
• W2914656225 hasAuthorship W2914656225A5035666187 @default.
• W2914656225 hasAuthorship W2914656225A5049307026 @default.
• W2914656225 hasAuthorship W2914656225A5061658744 @default.
• W2914656225 hasBestOaLocation W29146562251 @default.
• W2914656225 hasConcept C126322002 @default.
• W2914656225 hasConcept C141071460 @default.
• W2914656225 hasConcept C143998085 @default.
• W2914656225 hasConcept C203092338 @default.
• W2914656225 hasConcept C2776694085 @default.
• W2914656225 hasConcept C2776755627 @default.
• W2914656225 hasConcept C2777506904 @default.
• W2914656225 hasConcept C2778119113 @default.
• W2914656225 hasConcept C2778239845 @default.
• W2914656225 hasConcept C2779338263 @default.
• W2914656225 hasConcept C2779429289 @default.
• W2914656225 hasConcept C2780653079 @default.
• W2914656225 hasConcept C2780775027 @default.
• W2914656225 hasConcept C2781173314 @default.
• W2914656225 hasConcept C2781451048 @default.
• W2914656225 hasConcept C535046627 @default.
• W2914656225 hasConcept C71924100 @default.
• W2914656225 hasConceptScore W2914656225C126322002 @default.
• W2914656225 hasConceptScore W2914656225C141071460 @default.
• W2914656225 hasConceptScore W2914656225C143998085 @default.
• W2914656225 hasConceptScore W2914656225C203092338 @default.
• W2914656225 hasConceptScore W2914656225C2776694085 @default.
• W2914656225 hasConceptScore W2914656225C2776755627 @default.
• W2914656225 hasConceptScore W2914656225C2777506904 @default.
• W2914656225 hasConceptScore W2914656225C2778119113 @default.
• W2914656225 hasConceptScore W2914656225C2778239845 @default.
• W2914656225 hasConceptScore W2914656225C2779338263 @default.
• W2914656225 hasConceptScore W2914656225C2779429289 @default.
• W2914656225 hasConceptScore W2914656225C2780653079 @default.
• W2914656225 hasConceptScore W2914656225C2780775027 @default.
• W2914656225 hasConceptScore W2914656225C2781173314 @default.
• W2914656225 hasConceptScore W2914656225C2781451048 @default.
• W2914656225 hasConceptScore W2914656225C535046627 @default.
• W2914656225 hasConceptScore W2914656225C71924100 @default.
• W2914656225 hasIssue "Supplement 1" @default.
• W2914656225 hasLocation W29146562251 @default.
• W2914656225 hasOpenAccess W2914656225 @default.
• W2914656225 hasPrimaryLocation W29146562251 @default.
• W2914656225 hasRelatedWork W2028006583 @default.
• W2914656225 hasRelatedWork W2054697909 @default.
• W2914656225 hasRelatedWork W2107142310 @default.
• W2914656225 hasRelatedWork W2116109317 @default.
• W2914656225 hasRelatedWork W2414560200 @default.
• W2914656225 hasRelatedWork W2416637456 @default.
• W2914656225 hasRelatedWork W2600735778 @default.
• W2914656225 hasRelatedWork W2789166760 @default.
• W2914656225 hasRelatedWork W2914656225 @default.
• W2914656225 hasRelatedWork W2133000900 @default.
• W2914656225 hasVolume "132" @default.
• W2914656225 isParatext "false" @default.
• W2914656225 isRetracted "false" @default.
• W2914656225 magId "2914656225" @default.
• W2914656225 workType "article" @default.